Tanner CM - Search Results

1

Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE, Lang AE. Poewe W, et al. Among authors: tanner cm. Nat Rev Dis Primers. 2017 Mar 23;3:17013. doi: 10.1038/nrdp.2017.13. Nat Rev Dis Primers. 2017. PMID: 28332488 Review.

2

Liver enzyme abnormalities in Parkinson's disease.

Tanner CM. Tanner CM. Geriatrics. 1991 Aug;46 Suppl 1:60-3. Geriatrics. 1991. PMID: 1894148 Review.

3

Abnormal liver enzyme-mediated metabolism in Parkinson's disease: a second look.

Tanner CM. Tanner CM. Neurology. 1991 May;41(5 Suppl 2):89-91; discussion 92. doi: 10.1212/wnl.41.5_suppl_2.89. Neurology. 1991. PMID: 2041601 Review.

4

Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial.

Marras C, McDermott MP, Rochon PA, Tanner CM, Naglie G, Lang AE; Parkinson Study Group DATATOP Investigators. Marras C, et al. Among authors: tanner cm. Mov Disord. 2008 Apr 15;23(5):653-9; quiz 776. doi: 10.1002/mds.21853. Mov Disord. 2008. PMID: 18076084

5

Nicotine and Parkinson's disease: implications for therapy.

Quik M, O'Leary K, Tanner CM. Quik M, et al. Among authors: tanner cm. Mov Disord. 2008 Sep 15;23(12):1641-52. doi: 10.1002/mds.21900. Mov Disord. 2008. PMID: 18683238 Free PMC article. Review.

6

Urate as a predictor of the rate of clinical decline in Parkinson disease.

Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, Marras C, Kieburtz K, Rudolph A, Bogdanov MB, Schwid SR, Tennis M, Tanner CM, Beal MF, Lang AE, Oakes D, Fahn S, Shoulson I, Schwarzschild MA; Parkinson Study Group DATATOP Investigators. Ascherio A, et al. Among authors: tanner cm. Arch Neurol. 2009 Dec;66(12):1460-8. doi: 10.1001/archneurol.2009.247. Arch Neurol. 2009. PMID: 19822770 Free PMC article. Clinical Trial.

7

A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts.

Marras C, Lang AE, Eberly SW, Oakes D, Fahn S, Schwid SR, Hyson C, Shoulson I; Parkinson Study Group DATATOP and PRECEPT investigators. Marras C, et al. Mov Disord. 2009 Dec 15;24(16):2370-8. doi: 10.1002/mds.22828. Mov Disord. 2009. PMID: 19908310 Clinical Trial.

8

Teaching program for the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale: (MDS-UPDRS).

Goetz CG, Stebbins GT, Chmura TA, Fahn S, Poewe W, Tanner CM. Goetz CG, et al. Among authors: tanner cm. Mov Disord. 2010 Jul 15;25(9):1190-4. doi: 10.1002/mds.23096. Mov Disord. 2010. PMID: 20629138

9

Exploring the electrocardiogram as a potential tool to screen for premotor Parkinson's disease.

Valappil RA, Black JE, Broderick MJ, Carrillo O, Frenette E, Sullivan SS, Goldman SM, Tanner CM, Langston JW. Valappil RA, et al. Among authors: tanner cm. Mov Disord. 2010 Oct 30;25(14):2296-303. doi: 10.1002/mds.23348. Mov Disord. 2010. PMID: 20976736

10

Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts.

Marras C, McDermott MP, Marek K, Rochon P, Naglie G, Tanner CM, Rudolph A, Shoulson I, Lang AE; Parkinson Study Group DATATOP and PRECEPT investigators. Marras C, et al. Among authors: tanner cm. Mov Disord. 2011 Mar;26(4):608-13. doi: 10.1002/mds.23581. Epub 2011 Feb 1. Mov Disord. 2011. PMID: 21287602

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

339 results

Search Page